Motor outcome measures in patients with FKRP mutations: A longitudinal follow-up
- PMID: 32764098
- PMCID: PMC7713753
- DOI: 10.1212/WNL.0000000000010604
Motor outcome measures in patients with FKRP mutations: A longitudinal follow-up
Abstract
Objective: To test the hypothesis that we will be able to detect change in motor outcome measures over time in a cohort with mutations in FKRP.
Methods: Individuals with documented FKRP mutations were evaluated annually with a battery of established motor outcome measures including limited quantitative myometry and timed function measures. Results were analyzed using random coefficient regression to determine annual change in each measure. Due to the nonlinear progression through the lifespan of the study participants, pediatric (<19 years) and adult (≥19 years) cohorts were analyzed separately. Effect of genotype was evaluated in each cohort.
Results: Sixty-nine participants (30 pediatric, 44 adult) with at least 2 evaluations were included. There was a small but statistically significant decline in timed motor function measures in both pediatric and adult cohorts. Genotype significantly affected rate of decline in the pediatric but not the adult cohort. Some pediatric patients who are homozygous for the c.826C>A mutation showed improving motor performance in adolescence. Performance on the 10-meter walk/run was highly correlated with other timed function tests.
Conclusions: There is a slow annual decline in motor function in adults with FKRP mutations that can be detected with standard motor outcome measures, while the results in the pediatric population were more variable and affected by genotype. Overall, these analyses provide a framework for development of future clinical trials. The dystroglycanopathies natural history study (Clinical Trial Readiness for the Dystroglycanopathies) may be found on clinicaltrials.gov (NCT00313677).
© 2020 American Academy of Neurology.
Figures
References
-
- Muntoni F, Brockington M, Blake DJ, Torelli S, Brown SC. Defective glycosylation in muscular dystrophy. Lancet 2002;360:1419–1421. - PubMed
-
- Henry MD, Campbell KP. Dystroglycan inside and out. Curr Opin Cell Biol 1999;11:602–607. - PubMed
-
- Cohn RD. Dystroglycan: important player in skeletal muscle and beyond. Neuromuscul Disord 2005;15:207–217. - PubMed
-
- Bouchet-Seraphin C, Vuillaumier-Barrot S, Seta N. Dystroglycanopathies: about numerous genes involved in glycosylation of one single glycoprotein. J Neuromuscul Dis 2015;2:27–38. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical